Suppr超能文献

肺上皮细胞中过氧化物酶体增殖物激活受体 γ(PPARγ)下调促进慢性阻塞性肺疾病(COPD)中一种 PPARγ 激动剂可逆转的促炎表型。

Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD).

机构信息

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15240.

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213.

出版信息

J Biol Chem. 2014 Mar 7;289(10):6383-6393. doi: 10.1074/jbc.M113.536805. Epub 2013 Dec 24.

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition and a leading cause of death, with no available cure. We assessed the actions in pulmonary epithelial cells of peroxisome proliferator-activated receptor γ (PPARγ), a nuclear hormone receptor with anti-inflammatory effects, whose role in COPD is largely unknown. We found that PPARγ was down-regulated in lung tissue and epithelial cells of COPD patients, via both reduced expression and phosphorylation-mediated inhibition, whereas pro-inflammatory nuclear factor-κB (NF-κB) activity was increased. Cigarette smoking is the main risk factor for COPD, and exposing airway epithelial cells to cigarette smoke extract (CSE) likewise down-regulated PPARγ and activated NF-κB. CSE also down-regulated and post-translationally inhibited the glucocorticoid receptor (GR-α) and histone deacetylase 2 (HDAC2), a corepressor important for glucocorticoid action and whose down-regulation is thought to cause glucocorticoid insensitivity in COPD. Treating epithelial cells with synthetic (rosiglitazone) or endogenous (10-nitro-oleic acid) PPARγ agonists strongly up-regulated PPARγ expression and activity, suppressed CSE-induced production and secretion of inflammatory cytokines, and reversed its activation of NF-κB by inhibiting the IκB kinase pathway and by promoting direct inhibitory binding of PPARγ to NF-κB. In contrast, PPARγ knockdown via siRNA augmented CSE-induced chemokine release and decreases in HDAC activity, suggesting a potential anti-inflammatory role of endogenous PPARγ. The results imply that down-regulation of pulmonary epithelial PPARγ by cigarette smoke promotes inflammatory pathways and diminishes glucocorticoid responsiveness, thereby contributing to COPD pathogenesis, and further suggest that PPARγ agonists may be useful for COPD treatment.

摘要

慢性阻塞性肺疾病(COPD)是一种进行性炎症性疾病,也是主要的死亡原因,目前尚无治愈方法。我们评估了过氧化物酶体增殖物激活受体γ(PPARγ)在肺上皮细胞中的作用,PPARγ 是一种具有抗炎作用的核激素受体,其在 COPD 中的作用在很大程度上尚不清楚。我们发现,COPD 患者的肺组织和上皮细胞中 PPARγ 的表达减少,同时伴有磷酸化介导的抑制作用,而促炎核因子-κB(NF-κB)的活性增加。吸烟是 COPD 的主要危险因素,气道上皮细胞暴露于香烟烟雾提取物(CSE)同样会下调 PPARγ 并激活 NF-κB。CSE 还下调并翻译后抑制糖皮质激素受体(GR-α)和组蛋白去乙酰化酶 2(HDAC2),后者是糖皮质激素作用的重要核心抑制因子,其下调被认为导致 COPD 中糖皮质激素不敏感。用合成(罗格列酮)或内源性(10-硝基-油酸)PPARγ激动剂处理上皮细胞可强烈上调 PPARγ 的表达和活性,抑制 CSE 诱导的炎症细胞因子的产生和分泌,并通过抑制 IκB 激酶途径和促进 PPARγ 与 NF-κB 的直接抑制性结合来逆转其对 NF-κB 的激活。相比之下,通过 siRNA 敲低 PPARγ 会增强 CSE 诱导的趋化因子释放和 HDAC 活性降低,表明内源性 PPARγ 可能具有抗炎作用。结果表明,香烟烟雾对肺上皮细胞中 PPARγ 的下调促进了炎症途径并降低了糖皮质激素的反应性,从而导致 COPD 的发病机制,进一步表明 PPARγ 激动剂可能对 COPD 的治疗有用。

相似文献

3
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation.
Pulm Pharmacol Ther. 2023 Apr;79:102197. doi: 10.1016/j.pupt.2023.102197. Epub 2023 Jan 20.
7
Role of GPx3 in PPARγ-induced protection against COPD-associated oxidative stress.
Free Radic Biol Med. 2018 Oct;126:350-357. doi: 10.1016/j.freeradbiomed.2018.08.014. Epub 2018 Aug 15.
8
SIRT1/FoxO3 axis alteration leads to aberrant immune responses in bronchial epithelial cells.
J Cell Mol Med. 2018 Apr;22(4):2272-2282. doi: 10.1111/jcmm.13509. Epub 2018 Feb 7.
10
Airway epithelial cell PPARγ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice.
Am J Physiol Lung Cell Mol Physiol. 2015 Aug 1;309(3):L293-304. doi: 10.1152/ajplung.00287.2014. Epub 2015 May 29.

引用本文的文献

3
The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics.
Oxid Med Cell Longev. 2023 Dec 21;2023:2297559. doi: 10.1155/2023/2297559. eCollection 2023.
4
cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features.
Biochem Biophys Rep. 2023 Feb 16;34:101438. doi: 10.1016/j.bbrep.2023.101438. eCollection 2023 Jul.

本文引用的文献

1
The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD.
Eur Respir J. 2014 Feb;43(2):409-20. doi: 10.1183/09031936.00187812. Epub 2013 Jun 21.
2
PPARγ is an E3 ligase that induces the degradation of NFκB/p65.
Nat Commun. 2012;3:1300. doi: 10.1038/ncomms2270.
3
Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury.
J Immunol. 2012 Dec 1;189(11):5411-20. doi: 10.4049/jimmunol.1201487. Epub 2012 Oct 26.
5
Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease.
Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):603-14. doi: 10.1093/abbs/gmq071. Epub 2010 Aug 7.
7
Oxidative stress modulates PPAR gamma in vascular endothelial cells.
Free Radic Biol Med. 2010 Jun 15;48(12):1618-25. doi: 10.1016/j.freeradbiomed.2010.03.007. Epub 2010 Mar 17.
8
Histone deacetylase-2 and airway disease.
Ther Adv Respir Dis. 2009 Oct;3(5):235-43. doi: 10.1177/1753465809348648. Epub 2009 Oct 7.
9
Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats.
Pulm Pharmacol Ther. 2009 Aug;22(4):318-25. doi: 10.1016/j.pupt.2009.01.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验